Results for this period
Full year1 April 2025 to 31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in million yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The medical equipment market led overall performance, while overseas sales in the semiconductor and LCD markets and sales to the United States in the water treatment market remained strong. Manufacturing-related fixed costs temporarily increased due to changes in the product shipment mix aimed at production adjustments and inventory optimization, but operating profit increased as a result of higher revenue. Ordinary profit also increased due to higher equity-method investment income and foreign exchange gains, among other factors.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025 to 31 March 2026 |
| Net Sales | 47,692 million yen (YoY +4.2%) |
| Operating profit | 5,924 million yen (YoY +1.4%) |
| Ordinary income | 6,724 million yen (YoY +3.2%) |
| Profit attributable to owners of the parent | 4,835 million yen (YoY +8.2%) |
| Net income per share | ¥218.14 |
| Operating Margin | 12.4% |
| Equity ratio | End of the current fiscal period 74.0% / End of previous period 70.0% |
| Total assets | 55,844 million yen |
| Net assets | 41,482 million yen |
| Cash flows from operating activities | 5,251 million yen |
| Cash flows from investing activities | -3,385 million yen |
| Cash flows from financing activities | -1,277 million yen |
| Cash and cash equivalents at end of period | 8,888 million yen |
| Full-year earnings forecast | Net Sales 50,959 million yen (YoY +6.8%) / Operating profit 6,428 million yen (YoY +8.5%) / Ordinary income 6,986 million yen (YoY +3.9%) / Net income 5,149 million yen (YoY +6.5%) |
| Annual Dividend Forecast | 77 yen → 92 yen（+19.5%） |
| Payout ratio | 39.7% |
| Regional sales | 22,568 million yen (YoY +4.0%), 6,096 million yen (YoY +1.2%), 7,849 million yen (YoY +8.4%), 2,872 million yen (YoY +3.4%), 5,790 million yen (YoY +3.0%), 2,514 million yen |
| Depreciation and amortization | 1,264,625 thousand yen |
| Impairment loss | None recorded for the current period |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 151 thousand yen, Gain on sale of investment securities 584 thousand yen, Gain on Reversal of Foreign Currency Translation Adjustment Account upon Liquidation of Foreign Subsidiary 18,607 thousand yen / Extraordinary loss Loss on Disposal of Fixed Assets 250 thousand yen |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 1 company / Company name IWP Holding Company Limited |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 22,490,910 |
| Treasury Shares at Period-End | 307,565 |
| Factors Behind Changes in Business Performance | The medical equipment market led overall performance, while overseas sales in the semiconductor and LCD markets and sales to the United States in the water treatment market remained strong. Manufacturing-related fixed costs temporarily increased due to changes in the product shipment mix aimed at production adjustments and inventory optimization, but operating profit increased as a result of higher revenue. Ordinary profit also increased due to higher equity-method investment income and foreign exchange gains, among other factors. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The medical equipment market led overall performance, while overseas sales in the semiconductor and LCD markets and sales to the United States in the water treatment market remained strong. The Company expanded sales by pursuing a sales strategy centered on solution proposals in Japan and overseas. The increase in revenue, higher equity-method investment income and foreign exchange gains also contributed to performance.